VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
CVS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
CVSCVS Health Corp.
$85.81$103.8B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksCVSBalance Sheet

CVS Health Corp. (CVS) Balance Sheet

30Y historyFree accessUpdated daily

Total assets of $258.1B against equity of $80.5B and a debt-to-equity ratio of 1.24 suggest limited capital cushion to absorb an adverse reserve or earnings shock.

Income StatementBalance SheetCash FlowRatios

CVS Balance Sheet

Annual statement

CVS Balance Sheet

CVS Health Corp. (CVS) balance sheet — 30-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Total Assets258.07B261.06B253.22B249.73B228.28B233B230.72B222.45B196.46B95.13B94.46B92.44B74.19B71.53B66.22B64.54B62.17B61.64B60.96B54.72B20.57B15.28B14.55B10.54B9.65B8.64B7.95B7.28B6.69B5.98B5.69B
Asset Growth %1.38%3.1%1.4%9.4%-2.03%0.99%3.72%13.23%106.51%0.71%2.19%24.6%3.72%8.01%2.6%3.82%0.86%1.12%11.4%165.97%34.62%5.06%37.97%9.31%11.68%8.64%9.27%8.82%11.83%5.01%43.72%
Total Investment Assets4M35.01B31.34B26.28B23.87B26.14B23.81B19.69B18.25B223M87M88M34M88M5M5M4M5M027.5M00000000000
Long-Term Investments132.59B32.87B28.93B23.02B21.1B23.02B20.81B17.31B15.73B112M000000000000000000000
Short-Term Investments3.15B2.15B2.41B3.26B2.78B3.12B3B2.37B2.52B111M87M88M34M88M5M5M4M5M027.5M00000000000
Total Current Assets79.39B74.71B68.64B67.86B65.63B60.01B56.37B50.3B45.24B31.23B31.04B29.16B25.98B25.32B20.16B18.59B17.71B17.54B16.53B14.15B10.4B8.39B7.92B6.5B5.98B5.41B4.94B4.61B4.35B3.89B3.53B
Cash & Equivalents11.74B8.51B8.59B8.2B12.95B9.41B7.85B5.68B4.06B1.7B3.37B2.46B2.48B4.09B1.38B1.41B1.43B1.09B1.35B1.06B530.7M513.4M392.3M843.2M700.4M236.3M337.3M230M181M192.5M471.8M
Receivables163.15B39.78B36.47B35.23B27.28B24.43B21.74B19.62B17.63B13.18B12.16B11.89B9.69B8.73B6.48B6.05B4.92B5.46B5.38B4.58B2.38B1.84B1.76B1.35B1.02B966.2M824.5M699.3M650M452.4M350.7M
Other Current Assets4.19B5.03B3.08B3.15B3.54B5.29B5.28B5.11B4.58B945M660M722M1.85B1.37B1.27B1.08B655M646M637M477.5M374.5M319.9M309.1M287.2M248.5M288.8M217.2M233.2M328M364.8M378.2M
Goodwill & Intangibles441.36B110.99B118.59B120.51B102.95B108.15B110.69B112.87B115.2B52.08B51.76B51.98B37.92B36.07B36.15B36.33B35.45B35.81B35.94B34.35B4.51B2.59B2.77B1.29B1.23B1.19B818.5M706.9M725M711.5M721.7M
Goodwill85.48B85.48B91.27B91.27B78.15B79.12B79.55B79.75B78.68B38.45B38.25B38.11B28.14B26.54B26.39B26.46B25.67B25.68B25.49B23.92B3.2B0000000000
Intangible Assets24.22B25.51B27.32B29.23B24.8B29.03B31.14B33.12B36.52B13.63B13.51B13.88B9.77B9.53B9.75B9.87B9.78B10.13B10.45B10.43B1.32B2.59B2.77B1.29B1.23B1.19B818.5M706.9M725M711.5M721.7M
PP&E (Net)27.55B28.06B28.94B30.43B30.75B32.02B33.34B32.9B11.35B10.29B10.18B9.86B8.84B8.62B8.63B8.47B8.32B7.92B8.13B5.85B5.33B3.95B3.51B2.54B2.22B1.85B1.74B1.6B1.35B1.07B965.5M
Other Assets7.37B6.91B8.1B7.91B7.85B9.8B9.51B9.06B8.93B1.42B1.49B1.44B1.45B1.51B1.28B1.16B688M374M369M367.8M240.5M223.5M217.4M211.8M210.5M177.8M452.3M359.5M261M303M477.6M
Total Liabilities177.39B185.68B177.49B173.09B156.51B157.62B161.01B158.28B137.91B57.44B57.63B55.23B36.22B33.59B28.57B26.49B24.43B25.87B26.39B23.4B10.66B6.95B7.56B4.52B4.45B4.07B3.64B3.6B3.58B3.36B3.5B
Total Debt75.3B93.59B82.92B79.39B70.73B76B85.04B89B73.43B27B27.53B27.46B12.89B13.4B9.83B10.01B10.06B11.18B11.75B10.48B5.06B2.19B2.84B1.08B1.11B1.07B1.15B1.03B1.06B755.3M1.18B
Net Debt63.56B85.08B74.33B71.19B57.79B66.59B77.19B83.32B69.37B25.31B24.16B25B10.41B9.31B8.45B8.6B8.63B10.09B10.4B9.43B4.53B1.68B2.45B233.1M412.7M836.3M810.7M796.8M881M562.8M712.5M
Long-Term Debt57.22B72.88B60.53B58.64B50.48B51.97B59.21B64.7B71.44B22.18B25.61B26.27B11.63B12.84B9.13B9.21B8.65B8.76B8.06B8.35B2.87B1.59B1.93B753.1M1.08B810.4M536.8M558.5M276M288.9M1.18B
Short-Term Debt3.46B5.8B5.74B2.97B1.78B4.21B5.44B3.78B1.99B4.82B1.92B1.2B1.26B561M695M806M1.41B2.42B3.7B2.13B2.19B595M916.2M323.2M36.8M262.2M611.2M468.3M786M466.4M0
Total Current Liabilities93.1B88.69B84.61B79.19B69.42B67.81B62.02B53.3B44.01B30.65B26.25B23.17B19.03B15.43B14.15B11.96B11.07B12.3B13.49B10.77B7B4.58B4.86B3.49B3.11B3.07B2.96B2.89B3.13B2.91B2.12B
Accounts Payable17.88B59.38B15.89B14.9B14.84B12.54B11.14B10.49B8.93B8.86B7.95B7.49B6.55B5.55B5.07B4.37B4.03B3.56B3.8B3.59B2.52B2.47B2.28B1.67B1.71B1.54B1.35B1.45B1.29B1.23B1.05B
Deferred Revenue062M00000000000000000000000000000
Other Current Liabilities17.76B23.42B1.18B2.47B2.82B5.6B5.83B4.82B4.88B23M0000000002.48B346.3M000001B967.4M1.06B1.21B1.08B
Deferred Taxes22.76B1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K0001000K01000K1000K1000K1000K01000K
Other Liabilities10.5B-2.16B13.64B14.92B15.79B13.39B14.24B14.06B14.78B1.61B1.55B1.58B1.53B1.42B1.5B1.48B1.06B1.14B1.14B857.9M781.1M774.2M774.9M237.4M266.1M158.6M116M120.1M142M164.8M140.8M
Total Equity80.69B75.38B75.73B76.64B71.77B75.38B69.7B64.17B58.54B37.7B36.83B37.2B37.96B37.94B37.65B38.05B37.73B35.77B34.57B31.32B9.92B8.33B6.99B6.02B5.2B4.57B4.3B3.68B3.11B2.61B2.2B
Equity Growth %13.62%-0.46%-1.18%6.78%-4.79%8.15%8.62%9.61%55.31%2.34%-0.99%-2%0.07%0.76%-1.05%0.84%5.5%3.45%10.38%215.82%19.04%19.24%16.03%15.87%13.8%6.09%16.98%18.28%18.99%19.04%33.69%
Shareholders Equity80.5B75.21B75.56B76.46B71.47B75.08B69.39B63.86B58.23B37.69B36.83B37.2B37.96B37.94B37.65B38.05B37.7B35.77B34.57B31.32B9.92B8.33B6.99B6.02B5.2B4.57B4.3B3.68B3.11B2.61B2.2B
Minority Interest192M168M170M175M300M306M312M306M318M4M4M7M5M0030M34M00000000000000
Retained Earnings66.71B61.2B62.84B61.6B56.4B54.91B49.64B45.11B40.91B43.56B38.98B35.51B31.85B28.49B25B22.09B19.3B16.36B13.1B10.29B7.97B6.74B5.65B4.85B4.1B3.49B3.18B2.54B2.02B1.73B1.59B
Common Stock18M18M18M48.99B48.19B47.38B46.51B45.97B45.44B32.1B17M17M17M17M17M16M16M16M16M15.9M8.5M8.4M8.3M4.1M4.1M4.1M4.1M4M4M00
Accumulated OCI-595M406M-120M-297M-1.26B965M1.41B1.02B102M-165M-305M-358M-217M-149M-181M-172M-143M-135M-143M-395.5M-154.7M-204.3M-196.4M-200.1M-239M-219.9M-240.6M-257M-271M00
Return on Equity (ROE)14.1%2.34%6.06%11.24%5.86%11.03%10.73%10.81%-1.23%17.77%14.36%13.93%12.24%12.15%10.21%9.14%9.32%10.51%9.75%12.79%15%15.99%14.13%15.1%14.68%9.32%18.69%18.7%13.43%3.69%10.85%
Return on Assets (ROA)4.31%0.69%1.83%3.49%1.87%3.45%3.17%3.17%-0.41%6.99%5.69%6.29%6.37%6.67%5.91%5.46%5.54%6.03%5.55%7%7.64%8.21%7.32%8.39%7.84%4.98%9.8%9.1%6.07%1.52%4.31%
Equity / Assets31.27%28.87%29.91%30.69%31.44%32.35%30.21%28.85%29.8%39.62%38.99%40.25%51.17%53.04%56.86%58.95%60.7%58.03%56.72%57.24%48.2%54.51%48.03%57.12%53.88%52.88%54.15%50.58%46.53%43.73%38.58%
Debt / Equity0.93x1.24x1.09x1.04x0.99x1.01x1.22x1.39x1.25x0.72x0.75x0.74x0.34x0.35x0.26x0.26x0.27x0.31x0.34x0.33x0.51x0.26x0.41x0.18x0.21x0.23x0.27x0.28x0.34x0.29x0.54x
Book Value per Share62.5059.3160.0159.4154.2556.7253.0449.1756.0836.8134.1433.0432.4730.9429.4228.2527.4024.6723.5422.8311.629.908.507.456.415.735.394.503.843.315.15
Tangible BV per Share-22.47-28.01-33.97-34.01-23.57-24.65-31.20-37.32-54.27-14.05-13.83-13.130.041.521.181.281.66-0.03-0.93-2.216.336.825.135.854.894.234.363.642.942.413.46

Key Metrics

Growth RegimeMixed
ProfitabilityWeak
Balance SheetStrained
Cash FlowMixed
Top Statement Risk

Reserve adequacy and leverage pressure

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Equity Rebuild Lags Asset Expansion

According to recent SEC filings, CVS total assets moved from $253.0B in 2026Q1 to $258.1B in 2026Q3 while equity rose from $77.5B to $80.5B, suggesting the balance sheet is growing without a corresponding acceleration in retained capital generation.

The gap between asset growth and equity growth implies that much of the expansion is funded by liabilities, which stood at $177.4B in 2026Q3. Equity has recovered from the $72.9B trough in 2025Q3, but the pace of rebuilding appears modest relative to the scale of the balance sheet. Investors should monitor whether the balance sheet strengthens through earnings retention or remains dependent on reserve and debt growth.

Claims Reserves Track Elevated Loss Ratios

Based on EDBL's reported figures, CVS claims and loss balances reached $93.5B in 2026Q3 with a loss ratio of 86.3%, up from 84.4% in 2026Q1, indicating reserve intensity has risen alongside premium-driven exposure.

A loss ratio in the mid-80s leaves a narrow margin before the combined ratio, which reached 96.7%, approaches breakeven. The rise in claims balances relative to the prior period may reflect higher utilization rather than reserve strengthening, though the data cannot distinguish the two. Investors should monitor prior-year development disclosures to assess whether current reserves are adequate.

Thin Capital Buffer Against Leverage

As reported in financial statements, CVS carries a debt-to-equity ratio of 1.24 against an equity base of $80.5B, which leaves limited capacity to absorb an adverse reserve or earnings shock without further balance sheet strain.

Leverage at this level constrains flexibility for buybacks or acquisitions, and the modest 2.7% ROE in 2026Q3 suggests the equity base is not generating strong returns. Statutory RBC data is not provided, so capital adequacy relative to regulatory thresholds cannot be assessed directly. The most prudent reading is that capital is adequate for current operations but offers little cushion for a sustained deterioration in medical costs.

Reserve Timing Could Mask Underlying Risk

Based on EDBL's reported figures, the 2025Q3 combined ratio of 103.1% and net loss of $4.0B contrast with a 2026Q3 rebound, suggesting reported balance sheet recovery may depend on reserve timing that is not visible in summary figures.

The rapid swing in combined ratio and earnings implies that reserve estimates may have been adjusted between quarters, which can flatter or depress reported equity. If the recent improvement reflects favorable development rather than underlying cost containment, the apparent strengthening of the balance sheet could prove temporary. This warrants further investigation through reserve development tables before drawing firm conclusions about durable solvency.

CVS — Frequently Asked Questions

Quick answers to the most common questions about buying CVS stock.

What are the total assets of CVS Health Corp. (CVS)?

As of 2025, CVS Health Corp. (CVS) had total assets of $261.06B including $74.71B in current assets.

How much debt does CVS Health Corp. (CVS) have?

CVS Health Corp. (CVS) carries total debt of $93.59B, offset by $10.66B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of CVS Health Corp.?

CVS Health Corp. (CVS) has total shareholders' equity (book value) of $75.21B ($59.31 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is CVS Health Corp.'s current ratio and liquidity?

CVS Health Corp. (CVS) reported a current ratio of 0.84x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.